[ad_1]

Corindus Vascular Robotics trades as part of the medical devices industry and is part of the healthcare sector. The company CEO is Mark J. Toland. Corindus Vascular Robotics Inc is engaged in the design, manufacture, and sale of precision vascular robotic-assisted systems for use in interventional vascular procedures the CorPath System. Its product includes the CorPath 200 and CorPath GRX Systems.

Previous Intraday Trading Performance:

The CVRS stock showed a previous change of 3.83% with an open at 2.61 and a close of 2.71. It reached an intraday high of 2.72 and a low of 2.58.

SeekingAlpha:  Stereotaxis: Well Positioned To Become “Intuitive Surgical Of Endovascular Surgery” With Genesis Launch & Proprietary Catheter Development

Liquidity:

The stock has a market cap of $560.2m with 206.7m shares outstanding, of which the float is 205.7m shares. Trading volume reached 1,076,007 shares compared to its average volume of 1,609,710 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Corindus Vascular Robotics shares returned 3.04% and in the past 30 trading days it returned 29.05%. Over three months, it changed 105.30%. In one year it has changed 253.92% and within that year its 52-week high was 3.10 and its 52-week low was 0.70. CVRS stock is 287.09% above its 52 Week Low.

Our calculations show a 200 day moving average of 1.47 and a 50 day moving average of 2.25. Currently CVRS stock is trading 84.26% above its 200 day moving average.

Business Wire:  Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

Earnings:

The last annual fiscal EPS for the company was reported at -0.22 that ended on 31st of December 2018.

Below was the last reported quarterly diluted earnings per share:

1st Qtr of 2019 (Reported on 05/07/2019): -0.05
4th Qtr of 2018 (Reported on 03/12/2019): -0.04
3rd Qtr of 2018 (Reported on 11/06/2018): -0.04
2nd Qtr of 2018 (Reported on 08/07/2018): -0.06
1st Qtr of 2018 (Reported on 05/08/2018): -0.08

Indicators to Watch:

Based on the latest filings, there is 46.80% of institutional ownership. Short-interest was 13,686,394, which was 6.62% of shares outstanding. The short-interest ratio or days-to-cover ratio was 7.88. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 1.60.

Business Wire:  Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is -79.46%, price-to-sales is 43.75 and price-to-book is 382.89.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 0  :Past Performance Score
 4  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

[ad_2]

Source link